Aratana Therapeutics - InvestorRoom http://aratana.investorroom.com/ Aratana Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results http://aratana.investorroom.com/2018-02-13-Aratana-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2017-Financial-Results Tue, 13 Feb 2018 08:30:00 -0500 http://aratana.investorroom.com/2018-02-13-Aratana-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2017-Financial-Results GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017 http://aratana.investorroom.com/2018-01-18-GALLIPRANT-R-grapiprant-tablets-Named-Best-Companion-Animal-Product-for-2017 Thu, 18 Jan 2018 08:00:00 -0500 http://aratana.investorroom.com/2018-01-18-GALLIPRANT-R-grapiprant-tablets-Named-Best-Companion-Animal-Product-for-2017 Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe http://aratana.investorroom.com/2018-01-11-Elanco-Aratana-Announce-Marketing-Authorization-of-GALLIPRANT-R-grapiprant-tablets-in-Europe Thu, 11 Jan 2018 08:20:00 -0500 http://aratana.investorroom.com/2018-01-11-Elanco-Aratana-Announce-Marketing-Authorization-of-GALLIPRANT-R-grapiprant-tablets-in-Europe Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic http://aratana.investorroom.com/2017-12-20-Aratana-Therapeutics-Granted-Conditional-License-for-a-Canine-Osteosarcoma-Therapeutic Wed, 20 Dec 2017 08:05:00 -0500 http://aratana.investorroom.com/2017-12-20-Aratana-Therapeutics-Granted-Conditional-License-for-a-Canine-Osteosarcoma-Therapeutic Aratana Therapeutics Announces Study Results for AT-016 http://aratana.investorroom.com/2017-12-15-Aratana-Therapeutics-Announces-Study-Results-for-AT-016 Fri, 15 Dec 2017 16:15:00 -0500 http://aratana.investorroom.com/2017-12-15-Aratana-Therapeutics-Announces-Study-Results-for-AT-016